Jentadueto (linagliptin;metformin hydrochloride)
- Region
- 🇪🇺 EU
- Active substance
- linagliptin;metformin hydrochloride
- Company
- Boehringer Ingelheim International GmbH
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Thu 19 Jul 2012
- Application
- EMEA/H/C/002279
- ATC
- A10BD11
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with type-2 diabetes mellitus: Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin. Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Regulatory milestones
Jentadueto (linagliptin, metformin hydrochloride): DHPC sent to healthcare professionals
Quality defect; Diabetes Mellitus, Type 2 · source
Follow Jentadueto
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.